LLY - Eli Lilly and Company
| Previous Close | 119.16 |
| Open | 115.58 |
| Bid | 116.02 x 1400 |
| Ask | 116.98 x 1000 |
| Day's Range | 115.02 - 116.90 |
| 52 Week Range | 73.69 - 119.84 |
| Volume | 8,288,938 |
| Avg. Volume | 4,805,522 |
| Market Cap | 114.588B |
| Beta (3Y Monthly) | 0.59 |
| PE Ratio (TTM) | 268.02 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.58 (2.17%) |
| Ex-Dividend Date | 2019-02-14 |
| 1y Target Est | N/A |
- PR Newswire•3 days ago
Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients
REACH-2 is the first positive Phase 3 hepatocellular carcinoma trial in a biomarker-selected population known for poor prognosis Pooled data analyses of AFP-High patients in the REACH-2 and REACH trials ...
- PR Newswire•3 days ago
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO®
INDIANAPOLIS, Jan. 18, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) today reported that the results of ANNOUNCE, the Phase 3 study of LARTRUVO® (olaratumab), in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma (STS), did not confirm the clinical benefit of LARTRUVO in combination with doxorubicin as compared to doxorubicin, a standard of care treatment.
- GlobeNewswire•6 days ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether the Sale of Loxo Oncology, Inc. to Eli Lilly and Company is Fair to Shareholders
NEW YORK, Jan. 15, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Loxo Oncology, Inc. (“Loxo.
- GlobeNewswire•12 days ago
MERGER ALERT – BDMS, LOXO and MB: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
NEW YORK, Jan. 09, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.
- GlobeNewswire•12 days ago
Report: Exploring Fundamental Drivers Behind Virtusa, Eli Lilly, Cree, NewJersey Resources, Getty Realty, and PennantPark Investment — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Jan. 09, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•13 days ago
WEISSLAW LLP: Loxo Oncology, Inc. Acquisition May Not Be In The Best Interests of LOXO Shareholders
NEW YORK , Jan. 8, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Loxo Oncology, Inc. ("LOXO" ...
- GlobeNewswire•14 days ago
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Loxo Oncology, Inc. (LOXO) on Behalf of Stockholders and Encourages LOXO Investors to Contact the Firm
NEW YORK, Jan. 07, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Loxo Oncology, Inc. (NASDAQ: LOXO) on behalf of.
- PR Newswire•14 days ago
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Loxo Oncology, Inc.
NEW YORK , Jan. 7, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Loxo Oncology, Inc. (NASDAQ: LOXO) and its board of directors for breach of fiduciary duty concerning the ...
- GlobeNewswire•14 days ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Loxo Oncology, Inc. to Eli Lilly and Company is Fair to Shareholders
NEW YORK, Jan. 07, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Loxo Oncology, Inc. (“Loxo.
- Business Wire•14 days ago
Bigfoot Biomedical Announces Next Step for Connected Insulin Injection System
Bigfoot Biomedical, Inc., a diabetes company using artificial intelligence to develop solutions for optimizing the dosing and delivery of insulin, today announced a non-exclusive cooperation agreement with Eli Lilly and Company (LLY) to support integration of Lilly’s insulin products into Bigfoot’s systems currently in development. More than 5 million people in the US who live with type 1 and insulin-requiring type 2 diabetes use injections as their delivery method for insulin therapy, but insulin dosing for glucose management requires a complex set of guidelines, there are few tools to track insulin injection administration, and there is a lack of robust solutions to support healthcare providers in their efforts to implement the prescribed insulin regimens.
- PR Newswire•14 days ago
Lilly Announces Agreement To Acquire Loxo Oncology
Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines through the addition of a marketed therapy and a pipeline of highly selective potential medicines for patients with genomically defined cancers. Loxo Oncology's pipeline includes LOXO-292, an oral RET inhibitor being studied across multiple tumor types, which recently was granted Breakthrough Therapy designation by the FDA and could launch in 2020. Loxo Oncology's Vitrakvi® (larotrectinib) is an oral TRK inhibitor developed and commercialized in collaboration with Bayer that was recently approved by the FDA.
- GlobeNewswire•14 days ago
Lilly Announces Agreement To Acquire Loxo Oncology
Acquisition will broaden the scope of Lilly’s oncology portfolio into precision medicines through the addition of a marketed therapy and a pipeline of highly selective potential medicines for patients with genomically defined cancers. Loxo Oncology’s pipeline includes LOXO-292, an oral RET inhibitor being studied across multiple tumor types, which recently was granted Breakthrough Therapy designation by the FDA and could launch in 2020. Loxo Oncology’s Vitrakvi® (larotrectinib) is an oral TRK inhibitor developed and commercialized in collaboration with Bayer that was recently approved by the FDA.
- PR Newswire•18 days ago
Lilly to Participate in J.P. Morgan Healthcare Conference
INDIANAPOLIS , Jan. 3, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 . David A. Ricks , Lilly's ...
- PR Newswire•last month
Lilly Announces Financial Guidance, Reviews Commercial Performance, and Highlights Promising Pipeline Opportunities at Investment Community Meeting
Earnings per share (EPS) for 2019 are expected to be in the range of $5.52 to $5.62 on a reported basis and $5.90 to $6.00 on a non-GAAP basis, each excluding approximately $.08 per share for the non-controlling interest in Elanco Animal Health. Having launched 10 new medicines over the past five years, the company expects continued pipeline progress in 2019, including U.S. regulatory action for nasal glucagon for hypoglycemia and lasmiditan for acute migraine, as well as new indications for several medicines. The company has revised its 2020 minimum financial expectations and now expects at least 6 percent compound annual revenue growth from 2015 to 2020 for the full company, and at least 7 percent compound annual revenue growth for its human pharmaceutical business.
- PR Newswire•last month
Lilly Announces 15 Percent Dividend Increase
INDIANAPOLIS , Dec. 19, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 15 percent increase in its quarterly dividend. The dividend for the first quarter ...
- PR Newswire•last month
Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies
INDIANAPOLIS and BERKLEY, Calif., Dec. 18, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and Aduro Biotech, Inc. (ADRO) today announced a research collaboration and exclusive license agreement for Aduro's cGAS-STING Pathway Inhibitor program for the research and development of novel immunotherapies for autoimmune and other inflammatory diseases. Aduro's cGAS-STING Pathway Inhibitor program aims to discover and develop inhibitors of the intracellular stimulator of interferon genes (STING) pathway, which can modulate the immune response associated with various autoimmune diseases. As part of the agreement, Lilly will gain access to novel molecules from Aduro that are designed to inhibit the cGAS-STING pathway.
- PR Newswire•last month
Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning prognosis
- Subgroup analyses demonstrate consistent benefit in subgroups of patients with a more concerning prognosis such as those with liver metastases, PR-negative disease, high tumor grade, or shorter treatment-free ...
- PR Newswire•last month
Lilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
INDIANAPOLIS , Dec. 17, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today Taltz ® (ixekizumab) met the primary and all major secondary endpoints in the Phase 3b /4 SPIRIT-H2H study, ...
- PR Newswire•last month
Lilly to Acquire Pre-Clinical Pain Program from Hydra Biosciences
INDIANAPOLIS, Dec. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced an agreement with Hydra Biosciences to acquire all assets related to Hydra's pre-clinical program of TRPA1 antagonists, part of the Transient Receptor Potential (TRP) family of ion channels, that is currently being studied for the potential treatment of chronic pain syndromes. "At Lilly, we are committed to developing new treatment options for people struggling with chronic pain," said Mark Mintun, M.D., vice president of pain and neurodegeneration research at Lilly. "We are very excited to be transitioning this program into Lilly, given their depth of experience in drug development and commercialization," said Russell Herndon, Hydra Biosciences president and chief executive officer.
- PR Newswire•last month
Lilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors
INDIANAPOLIS and SAN MATEO, Calif., Dec. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and Evidation Health, a health and measurement company that helps innovative life sciences and health care companies understand how everyday behavior and health interact, announced today that they have expanded their collaboration with a multi-year agreement to provide Lilly with global access to Evidation's Andromeda data platform. As a result of this announcement, Lilly scientists and researchers across therapeutic portfolios will have access to Evidation's data platform with the goal of uncovering new ways to measure and understand a patient's health by accessing consented data derived from smartphones, connected sensors, wearables, and even his or her own voice.
- PR Newswire•last month
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
INDIANAPOLIS, Dec. 13, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to baricitinib, which is being studied for the treatment of systemic lupus erythematosus (SLE). The Fast Track designation process aims to facilitate the development and expedite the review of new medicines that treat serious conditions and fill unmet medical needs, with the goal of delivering potentially important therapies to patients sooner. "There has been only one new treatment for SLE approved in the U.S. in the past 50 years, and Lilly is excited to be at the forefront of potentially bringing a new treatment option to patients with this chronic, multi-organ autoimmune disease that can cause widespread tissue damage," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly.
- PR Newswire•last month
Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease
RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 13, 2018 /PRNewswire/ -- The Duke Clinical Research Institute (DCRI) is leading a new clinical study to optimize care for people with type 2 diabetes and cardiovascular disease through evaluation of a multidisciplinary approach at cardiology clinics across the U.S. The research program, COORDINATE-Diabetes (COOrdinating CaRDIology CliNics RAndomized Trial of Interventions to Improve OutcomEs), will be funded by Boehringer Ingelheim and Eli Lilly and Company (LLY). "The public health impact of type 2 diabetes and cardiovascular disease in the U.S. is immense," said Christopher Granger, M.D., professor of medicine in the Division of Cardiology at Duke University and lead researcher for COORDINATE-Diabetes.
- Business Wire•last month
AC Immune and Lilly Announce License and Collaboration Agreement
AC Immune to receive an initial upfront payment of CHF80 million and will be eligible for CHF60 million in potential near-term development milestones, up to approximately CHF1.7 billion in other potential development, regulatory and commercial milestones, and low double-digit royalties. Lilly to purchase $50 million note, convertible to equity position in AC Immune. AC Immune SA (ACIU) and Eli Lilly and Company (LLY) today announced that the two companies have signed a license and collaboration agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases.
- PR Newswire•last month
Lilly and AC Immune Announce License and Collaboration Agreement
AC Immune to receive an initial upfront payment of CHF80 million and will be eligible for CHF60 million in potential near-term development milestones, up to approximately CHF1.7 billion in other potential development, regulatory and commercial milestones, and low double-digit royalties. Eli Lilly and Company (LLY) and AC Immune SA (ACIU) today announced that the two companies have signed a license and collaboration agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease (AD) and other neurodegenerative diseases.